Open Access

Identification of proteins involved in the pancreatic exocrine by exogenous ghrelin administration in Sprague-Dawley rats

  • Kyung-Hoon Lee1,
  • Tao Wang1,
  • Yong-Cheng Jin2,
  • Sang-Bum Lee1,
  • Jin-Ju Oh1,
  • Jin-Hee Hwang1,
  • Ji-Na Lim1,
  • Jae-Sung Lee1 and
  • Hong-Gu Lee1Email author
Journal of Animal Science and Technology201456:6

DOI: 10.1186/2055-0391-56-6

Received: 25 April 2014

Accepted: 7 May 2014

Published: 5 June 2014

Abstract

The aims of study were to investigate the effects of intraperitoneal (i.p.) infusion of ghrelin on pancreatic α-amylase outputs and the responses of pancreatic proteins to ghrelin that may relate to the pancreatic exocrine. Six male Sprague-Dawley rats (300 g) were randomly divided into two groups, a control group (C, n = 3) and a treatment group (T, 10.0μg/kg BW, n = 3). Blood samples were collected from rat caudal vein once time after one hour injection. The concentrations of plasma ghrelin, cholecystokinin (CCK) and alfa-amylase activity were evaluated by enzyme immunoassay (EIA) kit. Two-dimensional gel electrophoresis (2-DE) analysis was conducted to separate the proteins in pancreas tissue. Results showed that the i.p. infusion of ghrelin at doses of 10.0 μg/kg body weight (BW) increased the plasma ghrelin concentrations (p = 0.07) and elevated the plasma CCK level significantly (p < 0.05). Although there was no statistically significant, the α-amylase activity tended to increase. The proteomics analysis indicated that some pancreatic proteins with various functions were up- or down- regulated compared with control group. In conclusion, ghrelin may have role in the pancreatic exocrine, but the signaling pathway was still not clear. Therefore, much more functional studies focus on these found proteins are needed in the near future.

Keywords

Alfa-amylase activity Cholecystokinin Ghrelin Pancreatic exocrine Sprague-Dawley rats Two-dimensional gel electrophoresis

Background

Ghrelin is a 28-amino-acid peptide isolated from the rat stomach in 1999 which is mainly produced by X/A-like cells in the oxyntic mucosa [1]. It was also found in other parts like hypothalamus, pituitary gland, lung, kidney [24], duodenum, ileum, colon and pancreas [5]. The ghrelin receptors (GHS-R) have been detected in many central and peripheral tissues and pancreatic α-cells, β-cells, exocrine cells. Ghrelin shows a number of actions at the gastrointestinal tract level. It is well known as a stronger activator of growth hormone (GH) through central nervous system (CNS) and modulation of food intake. And it also exhibits lots of other biological activities including energy expenditure, stimulation of lactotroph and corticotroph secretion, influence on sleep and behavior or modulation of heart rate and blood pressure ([69]; Assakawa et al. [10]).

Recent studies demonstrated that ghrelin could modulate exocrine secretions as well as pancreatic endocrine secretions. There were two opposite theories. First, Zhang and coworkers demonstrated that intravenous administration of ghrelin to the rats produced inhibition of enzyme secretion, and that this inhibitory effect of ghrelin on pancreatic exocrine secretion is indirect and may be exerted at the level of intrapancreatic neurons [11]. In contrast, other studies revealed that central as well as peripheral administration of ghrelin significantly increased pancreatic fluid and protein output, though the activation of vagal centers in the brainstem and stimulation of vagal efferent nerves [12, 13]. It is generally believed that, in the intestinal phase, stimulation of pancreatic enzyme secretion depends, in the main part, on the neuronal mechanism involved in the CCK release and activation of cholinergic vago-vagal enteropancreatic reflex. However, these physiological roles of ghrelin in the modulation of exocrine pancreatic functions are still unclear (Gherlaldoni et al. [14]).

Therefore, this study was conducted to determine the effects of exogenous ghrelin, given intraperitoneal (i.p.) on plasma CCK level and α-amylase output in the sprague-dawley rats. Meanwhile, the responses of pancreatic proteins to ghrelin were also analyzed using the 2-DE system.

Methods

Materials

Rat ghrelin peptide was obtained from Bachem (Bubendorf, Switzerland). Rat plasma ghrelin and CCK enzyme immunoassay kit were purchased from Phoenix Pharmaceuticals (Mountain View, CA, USA). The α-amylase activity analyzed using an EnzyChrom™ a-Amylase Assay Kit (ECAM-100).

Animals

Sprague-Dawley rats (300 g) (Samtaco, Osan, Korea) were used for all experiments. Animals were housed at one animal per cage on a 12/12 h light cycle (lights on at 8 am) and given access to food and water ad libitum. Ghrelin (0.1, 1.0, 10.0 ug/kg, respectively) were injected intraperitoneally in rats. One hour after injection, blood samples (1 ml) were collected from rat caudal vein once time into heparined tube and immediately centrifuged (3,000 rpm/min, 15 min) to obtain the plasma. Aliquots of plasma were stored at -80°C till analyzed. Then rats were anaesthetized via intramuscular injection of zoletil (Vetbutal) at a dose of 15.0 mg/300 g (BW). And the rat pancreas tissues were collected. All experimental procedures were in accordance with the “Guidelines for the Care and Use of Experimental Animals of Pusan National University”.

Determination of plasma ghrelin, CCK concentration and α-amylase activity

The plasma ghrelin and CCK concentration were separately determined by enzyme immunoassay kit (Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). The plasma α-amylase activity analyzed using an EnzyChrom™ a-Amylase Assay Kit (ECAM-100, BioAssay Systems, Hayward, CA, USA). All the operations were done followed the kit manual.

Pancreas sample preparation and 2-DE analysis

Pancreatic tissues were collected and then pulverized into powder under liquid nitrogen and stored at -80°C until use. Tissues (0.5 g) were homogenized in 1ml lysis solution containing 7 M urea, 2 M thiourea, 4% chaps, 40 mM Tris, 65 mM DTT, 0.5% IPG buffer and 1X protease inhibitor (GE Healthcare, Piscataway, New Jersey, USA). This mixture was stirred every 5 min for 30 min and then centrifuged at 14,000 rpm for 30 min at 20°C. The supernatant was then stored in aliquots at -80°C until analysis.

2-DE was performed of pooling pancreatic tissue samples from three animals in each group. Briefly, protein samples were diluted into isoelectric focusing (IEF) buffer containing 6 M urea, 2 M thiourea, 1% 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonate (CHAPS), 0.002% bromophenol blue, 0.5% phamalyte (pH 3-10NL) and 65 mM dithiothreitol (DTT). Then 100 μg protein smaples of control or treatment was loaded on Immobiline DryStrip gels (pH 3-10NL, 18 cm, GE Healthcare) for rehydration for 12 h at 20°C. The IEF procedures were performed using an IEF electrophoresis unit (GE Healthcare) following the manufacturer’s protocols. The following voltage program was used after the 12 h rehydration: linear ramp from 500 to 1000 V over 2 h, then a constant voltage of 8000 V for 7 h to give a total of 56,000 V h. After focusing, gel strips were equilibrated in a solution containing 50 mM Tris/HCl (pH 8.8), 6 M urea, 2% SDS, 30% glycerol, 0.002% w/v bromophenol blue and DTT for 15 min, followed by incubation in the same solution but replacing DTT with 135 mM iodoacetamide (IAA) for another 15 min. After that the equilibrated strips were inserted into sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (18 cm, 12%). SDS-PAGE was performed using an Ettan DALT 2-D gel system (GE Healthcare). Upon completion, gels were stained using a PluseOne Silver Staining Kit (GE Healthcare). The silverstained gels were scanned using an Umax scanner (PowerLook 2100XL, UMAX Technologies, Inc., Dallas, TX, USA). Scanned gel images were processed by Proteomweaver™ 2-D Analysis Software (Definiens AG, Munich, Germany).

Statistical analysis

Data are presented as mean ± standard error of the mean (SEM). The group mean values were compared with an independent sample t-test (SPSS 14.0, Chicago, IL, USA). A p-value <0.05 was considered to be statistically significant.

Results and discussion

The i.p. infusion of ghrelin at doses of 10.0 μg/kg body weight (BW) increased the plasma ghrelin concentrations (p = 0.07) and elevated the plasma CCK level significantly (p < 0.05). Although there was no statistically significant, the α-amylase activity tended to increase (Table 1). These data indicated that ghrelin may have role in pancreatic exocrine secretion through the stimulation of CCK release and activation of dorsal vagal nerve. CCK is one of the major gut hormones which released from duodenal mucosa I cells. It can stimulate pancreatic exocrine secretion via activation of CCK1 receptors and entero-pancreatic vago-vagal reflex [1519]. Whether CCK plays a role in the exocrine secretion response to ghrelin is unknown.
Table 1

Relationship between plasma G.I. hormones and α-amylase activity

Items

Ghrelin (ng/ml)

CCK (ng/ml)

α-amylase (U/L)

Control1

0.202 ± 0.1522*

5.745 ± 2.428

3791.799 ± 208.308

Treatment1

3.223 ± 2.140

11.306 ± 3.937

4210.847 ± 262.825

1Control = vehicle/500 uLSaline, Treatment = Ghrelin (10.0 ug/kg)/500 uLSaline.

2Data are mean ± SEM and *means significantly different, p < 0.05 (Student’s paired t-test).

The response of pancreatic proteins to ghrelin administration were analyzed by 2-DE in order to get a better understanding of the mechanisms involved in the ghrelin-exocrine secretion through CCK signal. Eight spots ranging from 6 to 200 kDa were detected differently expressed in the pancreatic protein map (Figure 1). One spot was up-regulated and six were down-regulated compared with control group. One spot was found only expressed in treatment group. These proteins were classified according to their functions (Table 2). Three down-regulated proteins eukaryotic translation initiation factor 5A-1 (eIF5A), peroxiredoxin IV (PRx IV) and ubiquinol-cytochrome c reductase (UQCR) were particular interested. eIF5A is involved in biosynthesis of pancreatic enzyme by increasing plasma CCK level [20]. And this data was different with ours. Judging by our reports, ghrelin may affect on pancreatic exocrine secretion via other factors as well as releasing CCK. Also, Yannick demonstrated that UQCR and PRx IV down-regulated biosynthesis of insulin related to diabetes [21]. Synthetically, when the effects of exogenous ghrelin, given intraperitoneal (i.p.) on pancreatic exocrine secretion, we have to consider other factor like growth hormone related to insulin synthesis as involving the CCK release and activation of cholinergic vago-vagal enteropancreatic reflex.
https://static-content.springer.com/image/art%3A10.1186%2F2055-0391-56-6/MediaObjects/40781_2014_Article_6_Fig1_HTML.jpg
Figure 1

Representative silver-stained 2-DE images of the normal rat pancreas (left) and treated rat pancreas by Ghrelin (right).

Table 2

Identification of differentially altered protein spots in rat pancreas by ESI/Q-TOF MS

Spot

Protein name

Peptide match

Protein score

Mass (bp)

Expression (treatment/control)

Cell growth and proliferation

8109

Eukaryotic translation initiation factor 5A-1

295

98.23

16821.4

Down

Gluconeogenesis

9071

Malate dehydrogenase, mitochondrial precursor

40

100.29

35660.8

Down

De nove purine biosynthesis

9447

Similar to adenylosuccinate lyase

67

214.27

54817

Up

Oxidative stress

6858

PRx IV

44

104.23

30988.1

Down

7120

Thiosulfate sulfurtransferase

392

154.28

33385.8

Down

9624

Sarcosine dehydrogenase, mitochondrial precursor

115

238.23

101578.9

Only Treatment

Others

8437

Ubiquinol-cytochrome c reductase iron-sulfur subunit, mitochondrial precursor

55

100.32

29427.2

Down

9537

Carbonic anhydrase 3

297

148.26

29412.7

Down

Conclusions

In conclusion, our result suggest a role of ghrelin on pancreatic exocrine, but the protein concerning with mechanism functional study was uncompleted. And some following functional study of proteins will be done in the near future.

Declarations

Acknowledgments

This research was supported by Bioindustry Technology Development Program (313020041SB010) for Ministry of Agriculture, Food and Rural Affairs, Republic of Korea.

Authors’ Affiliations

(1)
Department of Animal Science and Technology, College of Animal Bioscience & Technology, Konkuk University
(2)
Department of Animal Science, College of Animal Science and Veterinary Medicine, Jilin University

References

  1. Kojima M, Hasoda H, Date Y, Nakazato M, Matsou H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999, 402: 656-660. 10.1038/45230.View ArticlePubMedGoogle Scholar
  2. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E: Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002, 440 (2–3): 235-254.View ArticlePubMedGoogle Scholar
  3. Korbonits M, Kojima M, Kangawa K, Grossman AB: Presence of ghrelin in normal and adenomatous human pituitary. Endocrine. 2001, 14: 101-104. 10.1385/ENDO:14:1:101.View ArticlePubMedGoogle Scholar
  4. Volante M, Fulcheri E, Allia E, Cerrato M, Pucci A, Papotti M: Ghrelin expression in fetal infant and adult human lung. J Histochem Cytochem. 2002, 50: 1013-1021. 10.1177/002215540205000803.View ArticlePubMedGoogle Scholar
  5. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthetized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000, 141: 4255-4261.PubMedGoogle Scholar
  6. Ghigo E, Arvat E, Giordano R, Broglio F, Gianotti L, Maccario M, Bisi G, Graziani A, Papotti M, Muccioli G, Deghenghi R, Camanni F: Biologic activities of growth hormone secretagouges in humans. Endocrine. 2001, 14: 87-93. 10.1385/ENDO:14:1:087.View ArticlePubMedGoogle Scholar
  7. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature. 2000, 407: 908-913. 10.1038/35038090.View ArticlePubMedGoogle Scholar
  8. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S: A role for ghrelin in the central regulation of feeding. Nature. 2001, 409: 194-198. 10.1038/35051587.View ArticlePubMedGoogle Scholar
  9. Tolle V, Bassant MH, Zizzari P, Poindessous-Jazat F, Tomasetto C, Epelbaum J, Bluet-Pajot MT: Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep–wake patterns in rats. Endocrinology. 2002, 143: 1353-1361. 10.1210/endo.143.4.8712.View ArticlePubMedGoogle Scholar
  10. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Fujimiya M, Katsuura G, Makino S, Fujino MA, Kasuga M: A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology. 2001, 74: 143-147. 10.1159/000054680.View ArticlePubMedGoogle Scholar
  11. Broglio F, Prodam F, Me E, Riganti F, Lucatello B, Granata R, Benso A, Muccioli G, Ghigo E: Ghrelin: endocrine, metabolic and cardiovascular actions. J Endocrinol Invest. 2005, 28 (5 suppl): 23-25.PubMedGoogle Scholar
  12. Sato N, Kanai S, Takano S, Kurosawa M, Funakoshi A, Miyasaka K: Central administration of ghrelin stimulates pancreatic protein exocrine secretion via the vagus in conscious rats. Jpn J Physiol. 2003, 53 (6): 443-449. 10.2170/jjphysiol.53.443.View ArticlePubMedGoogle Scholar
  13. Li Y, Wu X, Zhao Y, Chen S, Owyang C: Ghrelin acts on the dorsal vagal complex to stimulate pancreatic protein secretion. Am J Physiol Liver Physiol. 2006, 290 (6): G1350-G1358.Google Scholar
  14. Ghelardoni S, Carnicelli V, Frascarelli S, Ronca-Testoni S, Zucchi R: Ghrelin tissue distribution: comparison between gene and protein expression. J Endocrinol Invest. 2006, 29 (2): 115-121. 10.1007/BF03344083.View ArticlePubMedGoogle Scholar
  15. Brzozowska I, Konturek PC, Brzozowski T, Konturek SJ, Kwiecien S, Pajdo R, Drozdowicz D, Pawlik M, Ptak A, Hahn EG: Role of prostaglandins, nitric oxide sensory nerves and gastrin in acceleration of ulcer healing by melatonin and its precursor; L-tryptophan. J Pineal Res. 2002, 32: 149-162. 10.1034/j.1600-079x.2002.1o811.x.View ArticlePubMedGoogle Scholar
  16. Jahovic N, Sener G, Cevik H, Ersoy Y, Arbak S, Yeğen BC: Amelioration of metotrexate-induced enteritis by melatonin in rats. Cell Biochem Function. 2004, 22: 169-178. 10.1002/cbf.1071.View ArticleGoogle Scholar
  17. Jaworek J, Nawrot K, Konturek SJ, Leja-Szpak A, Thor P, Pawlik WW: Melatonin and its precursor; L-tryptophan: influence on pancreatic amylase secretion in vivo and in vitro. J Pineal Res. 2004, 36: 156-164.View ArticleGoogle Scholar
  18. Leja-Szpak A, Jaworek J, Nawrot-Porabka K, Palonek M, Mitis-Musioł M, Dembiński A, Konturek SJ, Pawlik WW: Modulation of pancreatic enzyme secretion by melatonin and its precursor; L-tryptophan. Role of CCK and afferent nerves. J Physiol. 2004, 55: 441-451.Google Scholar
  19. Li Y, Owyang C: High affinity CCK-A receptors on the vagus nerve mediate CCK-stimulated pancreatic secretion in the rat. Am J Physiol. 1997, 273: G679-G685.PubMedGoogle Scholar
  20. Bragado MJ, Tashiro M, Williams JA: Regulation of the initiation of pancreatic digestive enzyme protein synthesis by cholecystokinin in rat pancreas in vivo. Gastroenterology. 2000, 119 (6): 1731-1739. 10.1053/gast.2000.20242.View ArticlePubMedGoogle Scholar
  21. Brunner Y, Schvartz D, Priego-Capote F, Couté Y, Sanchez JC: Glucotoxicity and pancreatic proteomics. J Proteomics. 2009, 71 (6): 576-591. 10.1016/j.jprot.2008.10.002.View ArticlePubMedGoogle Scholar

Copyright

© Lee et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement